Insider trading

Period: 120 months Stock: ARWR + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

216 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

216 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

216 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

216 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
216 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
216 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

216 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
20 Mar 2024
Lu Hongbo Director
Bought
$27.50K 1,000 at 27.50
3.1%
19 Mar 2024
Lu Hongbo Director
Bought
$28.00K 1,000 at 28.00
3.2%
Largest buy in 3 yrs
18 Mar 2024
Lu Hongbo Director
Bought
$27.49K 1,000 at 27.49
3.3%
First buy on file
6 Mar 2024
Myszkowski Kenneth Allen Chief Financial Officer
Sold at will
$1.41M 40,000 at 35.19
9.1%
Not planned
31 Jan 2024
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan 2×
$1.86M 57,499 at 32.35
1.5%
Planned (10b5-1)
12 Jan 2024
Hamilton James C Chief Discovery/Trans Medicine
Sold on a plan 2×
$292.90K 7,940 at 36.89
3.6%
Planned (10b5-1)
11 Jan 2024
Sold on a plan 2×
$179.81K 4,720 at 38.10
12.9%
Planned (10b5-1)
11 Jan 2024
Sold on a plan 2×
$149.76K 3,934 at 38.07
7.6%
Planned (10b5-1)
11 Jan 2024
Ferrari Mauro Director
Sold on a plan 2×
$119.79K 3,147 at 38.06
4.9%
Planned (10b5-1)
11 Jan 2024
GIVEN DOUGLAS B Director
Sold on a plan 2×
$110.79K 2,911 at 38.06
2.2%
Planned (10b5-1)
5 Jan 2024
Hamilton James C Chief Discovery/Trans Medicine
Sold on a plan 4×
$1.13M 32,143 at 35.18
12.8%
Planned (10b5-1)
5 Jan 2024
O'Brien Patrick COO and General Counsel
Sold on a plan 3×
$805.72K 22,841 at 35.27
4.7%
Planned (10b5-1)
5 Jan 2024
Myszkowski Kenneth Allen Chief Financial Officer
Sold on a plan 3×
$567.91K 16,104 at 35.27
3.5%
Planned (10b5-1)
5 Jan 2024
San Martin Javier Chief Medical Officer
Sold on a plan 3×
$292.80K 8,303 at 35.26
4.0%
Planned (10b5-1)
5 Jan 2024
Oliver Tracie Chief Commercial Officer
Sold on a plan
$2.51K 74 at 33.89
0.1%
Planned (10b5-1)
4 Jan 2024
O'Brien Patrick COO and General Counsel
Sold on a plan
$52.21K 1,600 at 32.63
0.4%
Planned (10b5-1)
3 Jan 2024
O'Brien Patrick COO and General Counsel
Sold on a plan 4×
$282.44K 8,749 at 32.28
2.1%
Planned (10b5-1)
3 Jan 2024
Hamilton James C Chief Discovery/Trans Medicine
Sold on a plan 3×
$202.78K 6,300 at 32.19
3.5%
Planned (10b5-1)
2 Jan 2024
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan 2×
$308.64K 9,952 at 31.01
0.3%
Planned (10b5-1)
20 Dec 2023
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan
$342.48K 12,000 at 28.54
0.3%
Planned (10b5-1)
20 Nov 2023
San Martin Javier Chief Medical Officer
Sold on a plan 2×
$567.32K 19,700 at 28.80
13.0%
Planned (10b5-1)
25 Oct 2023
Anzalone Christopher Richard Chief Executive Officer
Sold on a plan
$589.22K 24,338 at 24.21
0.6%
Planned (10b5-1)
28 Sep 2023
Sold at will
$40.81K 1,550 at 26.33
6.7%
Not planned
18 Sep 2023
Anzalone Christopher Richard Chief Executive Officer
Sold at will 2×
$1.62M 57,755 at 28.12
1.5%
Not planned
3 Jul 2023
Oliver Tracie Chief Commercial Officer
Sold at will
$315.14K 8,925 at 35.31
12.7%
Not planned
30 Jun 2023
Hamilton James C Chief Discovery/Trans Medicine
Sold at will
$106.59K 3,000 at 35.53
1.6%
Not planned
27 Jun 2023
Myszkowski Kenneth Allen Chief Financial Officer
Sold at will
$543.00K 15,000 at 36.20
3.8%
Not planned
5 May 2023
GIVEN DOUGLAS B Director
Sold at will
$265.85K 6,500 at 40.90
5.2%
Not planned
4 May 2023
Anzalone Christopher Richard Chief Executive Officer
Sold at will 2×
$1.98M 50,000 at 39.52
1.3%
Not planned
3 May 2023
Anzalone Christopher Richard Chief Executive Officer
Sold at will
$2.15M 54,928 at 39.14
1.4%
Not planned
3 Mar 2023
Sold, plan not stated
$370.58K 11,350 at 32.65
59.1%
Sold half or more
27 Feb 2023
GIVEN DOUGLAS B Director · indirect
Sold, plan not stated
$28.54K 875 at 32.62
6.3%
9 Jan 2023
Sold, plan not stated
$96.00K 3,200 at 30.00
10.0%
5 Jan 2023
O'Brien Patrick COO and General Counsel
Sold, plan not stated 2×
$560.85K 15,000 at 37.39
3.5%
5 Jan 2023
Hamilton James C Chief Discovery/Trans Medicine
Sold, plan not stated 2×
$516.23K 13,803 at 37.40
6.7%
3 Jan 2023
O'Brien Patrick COO and General Counsel
Sold, plan not stated 8×
$670.80K 17,500 at 38.33
4.6%
3 Jan 2023
Hamilton James C Chief Discovery/Trans Medicine
Sold, plan not stated 8×
$396.74K 10,338 at 38.38
6.6%
29 Dec 2022
Myszkowski Kenneth Allen Chief Financial Officer
Sold, plan not stated
$1.23M 30,625 at 40.00
8.3%
21 Nov 2022
San Martin Javier Chief Medical Officer
Sold, plan not stated 2×
$584.74K 19,500 at 29.99
17.6%
11 Feb 2022
Anzalone Christopher Richard Chief Executive Officer
Sold, plan not stated 4×
$7.60M 146,388 at 51.91
3.5%
5 Jan 2022
Myszkowski Kenneth Allen Chief Financial Officer
Sold, plan not stated 4×
$2.47M 40,000 at 61.70
7.9%
5 Jan 2022
O'Brien Patrick General Counsel
Sold, plan not stated 5×
$2.01M 32,500 at 61.72
8.5%
5 Jan 2022
Hamilton James C Senior Vice President
Sold, plan not stated 5×
$385.77K 6,250 at 61.72
3.9%
4 Jan 2022
Hamilton James C Senior Vice President
Sold, plan not stated 5×
$1.27M 19,375 at 65.49
10.7%
3 Jan 2022
Sold, plan not stated 3×
$291.24K 4,500 at 64.72
14.9%
3 Jan 2022
PERRY MICHAEL S Director
Sold, plan not stated 3×
$291.19K 4,500 at 64.71
5.0%
3 Jan 2022
Sold, plan not stated 3×
$291.18K 4,500 at 64.71
20.9%
3 Jan 2022
Sold, plan not stated 3×
$262.23K 4,050 at 64.75
45.0%
28 Dec 2021
Ferrari Mauro Director
Sold, plan not stated
$227.19K 3,400 at 66.82
8.5%
28 Dec 2021
GIVEN DOUGLAS B Director
Bought
$43.47K 655 at 66.37
0.6%
First buy on file
Showing 51–100 of 216. ← Newer Page 2 of 5 Older →